🇺🇸 FDA
Patent

US 9120811

6-(1H-indazol-6-YL)-N-(4-morpholinophenyl)imidazo[1,4-A]pyrazin-8-amine for treating leukemia or lymphoma

granted A61KA61K31/495A61P

Quick answer

US patent 9120811 (6-(1H-indazol-6-YL)-N-(4-morpholinophenyl)imidazo[1,4-A]pyrazin-8-amine for treating leukemia or lymphoma) held by GILEAD CONNECTICUT, INC. expires Mon Aug 27 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
GILEAD CONNECTICUT, INC.
Grant date
Tue Sep 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 27 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K31/495, A61P, A61P11/00, A61P11/02